Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
← catalyst calendarSponsored by Plus Therapeutics (industry) · PSTV — their whole pipeline →. With National Cancer Institute (NCI).
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
55estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2015-06-03 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2013-07-24 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioma
Intervention
- Drug: Rhenium Liposome Treatment — also filed as Rhenium-186 NanoLiposome
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Maximum Tolerated Dose
measured 90 days
Phase 2: Overall Survival
measured 12 Months
Publications
- PMID 39032243 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PSTV's whole pipeline · Catalyst calendar · Every registered study · What changed